Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer

BOTHELL, Wash., and TOKYO, Dec. 2, 2019 /PRNewswire/ — Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration agreement with Merck,...

Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson’s Disease with the Nanocatalytic Therapeutic, CNM-Au8

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ — Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study with its lead nanocatalytic therapy, CNM-Au8, for the treatment...
SEARCH FOR STUDIES